Avid Bioservices Inc (CDMO)

[biopharm]

This analysis also showed that the bavituximab combination group is performing as expected according to the original trial assumptions in terms of overall survival, while the docetaxel group is dramatically outperforming overall survival expectations based on the original trial assumptions and as compared to recently published studies.

No way one can argue with this statement released by Peregrine above.

I hope you remembered Peregrine saying they built in a buffer for the docetaxel-control arm.... remember?

This is becoming comical in trying to say much of anything else, than that Sunrise Bavituximab + Docetaxel arm beat out all historical Docetaxel arms (even with the buffer...!) and the Bavi+Docetaxel arm did not fail at all.

You have to admit, even your higher up CALICO friends are stunned that Peregrine keeps trotting along, adjusting with the times and has a pipeline that some wanted so bad..... that they twist the rules along the way, sometimes to the Fargo extremes.

Prepare for class action lawsuit dismissal

Prepare for cheap stock options for Peregrine BOD

Prepare for 175 Million shares of PPHM to be delivered to someone

In the meantime.... I sort of hope the deceptive illusions are kept up because the only way PPHM BOD's cash in on their stock options are with a higher stock price. That means anyone buying at this level will be in for an immediate AstraZeneca type of boost.

AstraZeneca ?? yep.... they are still standing around : )